AIM ImmunoTech CEO Thomas K. Equels Buys 22,000 Shares

What Happened

Thomas K. Equels, CEO & President and a director of AIM ImmunoTech Inc. (AIM), reported an open-market purchase of 22,000 common shares on 2026-09-15 at $0.22 per share, for a reported total value of $4,862. This was a purchase (Form 4 code "P"), which is generally considered a more informative signal than routine sales but does not by itself indicate a change in company outlook.

Key Details

• Transaction date and price: 2026-09-15, 22,000 shares at $0.22 per share (total reported $4,862).
• Transaction type: Open-market purchase (Form 4 code "P").
• Shares owned after transaction: Not specified in the portion of the filing provided.
• Filing timeliness: Form filed 2026-09-16 (one day after the reported transaction); filing appears timely under standard insider reporting rules.
• No footnotes, 10b5-1 plan, tax withholding, or option exercise were indicated in the provided transaction details.

Context

Purchases by executives like the CEO can be viewed by some investors as a modest bullish signal because they increase insider ownership, but the dollar amount here is small ($4.9K) and should be weighed with other information about the company and insider activity. This report records a straightforward open-market buy—no option exercise, award, or gift was involved.